Zydus joins the pack in India hep C launch; Vivo Capital raises $750M for U.S., Greater China;

> Zydus launched its hep C drug in India under Gilead ($GILD) license. Story

> Vivo Capital raises $750 million in 8th fund focused on U.S., Greater China. Release

> Mundipharma touted Betadine formulations effectiveness in minimizing risk of human-to-human Ebola transmission. Release (PDF)

> TaiGen signs agreement with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany in an investigator-initiated stem cell clinical trial. Release

> Australia's Mesoblast wins Japan External Trade Organization fast-track status on stem-cell investments. Release